Section
This review synthesizes emerging evidence comparing high-dose anti-CD25 (without methotrexate) versus low-dose anti-CD25 (with methotrexate) strategies for GVHD prophylaxis in haplo-HSCT, highlighting improved acute GVHD control and GRFS wi
CHIP and pre-treatment neutropenia do not significantly affect survival or main toxicities in CAR-T therapy for hematologic cancers but may predict specific inflammatory toxicities, indicating distinct risk profiles for patient management.
This article explores novel therapeutic strategies in acute myeloid leukemia by combining PI3K inhibitors with EZH1/2 dual inhibitors to overcome epigenetic resistance mechanisms in leukemic stem cells, offering promising pathways to preven
A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies
The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise
This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.
This study reveals that syndecan-4 shedding exacerbates deep vein thrombosis by promoting Piezo1-dependent endothelial-mesenchymal transition, with quercetin showing promise as a novel therapeutic Piezo1 inhibitor.
This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.
A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.
BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.
A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.
Hematologists and oncologists possess critical skills to address hematologic complications of acute radiation syndrome and are essential in bolstering mass casualty radiation response, utilizing existing resources and infrastructure for eff
A phase 2 trial demonstrates that adding venetoclax to pediatric chemotherapy regimens in adolescents and adults with newly diagnosed Philadelphia chromosome-negative ALL significantly improves MRD negativity and survival with manageable to
A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-all
This retrospective nationwide study from Italy evaluates real-life first-line treatments for primary mediastinal B-cell lymphoma, highlighting treatment patterns, clinical outcomes, and challenges in managing this rare lymphoma subtype.
This study analyzes treatment patterns, outcomes, and prognostic factors in 344 patients with transformed follicular lymphoma in the rituximab era, revealing poor event-free survival but moderate overall survival and high relapse rates, gui
This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with d
This article explores the pivotal role of Galectin-1 in enhancing monocyte-mediated inflammation in myeloproliferative neoplasms (MPNs) and highlights its potential as a novel therapeutic target through the TLR4-NF-κB signaling axis.
This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes i
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected ca
